References

Estimation of Clinical Trial Success Rates and Related Parameters

10.1093/biostatistics/kxx069 · 2019 · External reference

Accrual and Statistical Power Failure in Published Adjuvant Phase III Oncology Trials: A Comprehensive Analysis From 2013 to 2023

10.1016/j.esmoop.2024.103603 · 2024 · External reference

Evaluation of Overall Response Rate and Progression‐Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials

10.1158/1078-0432.ccr-17-1902 · 2018 · External reference

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

10.1002/cpt.3636 · 2025 · External reference

Unresolved reference

External reference

Role of Model‐Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision‐Making

10.1007/s11095-022-03288-w · 2022 · External reference

Progress and Opportunities to Advance Clinical cancer Therapeutics Using Tumor Dynamic Models

10.1158/1078-0432.ccr-19-0287 · 2020 · External reference

Model‐Based Drug Development in Oncology: What's Next?

10.1038/clpt.2013.8 · 2013 · External reference

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate cancer Trials: The Growth Rate Constant as an indicator of Therapeutic Efficacy

10.1158/1078-0432.ccr-10-1762 · 2011 · External reference

Evaluation of Tumor‐Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First‐Line Metastatic Colorectal cancer

10.1200/jco.2012.45.0973 · 2013 · External reference

A Model of Overall Survival Predicts Treatment Outcomes With Atezolizumab Versus Chemotherapy in Non‐Small Cell Lung cancer Based on Early Tumor Kinetics

10.1158/1078-0432.ccr-17-3662 · 2018 · External reference

New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)

10.1016/j.ejca.2008.10.026 · 2009 · External reference

Prediction of Overall Survival in Patients Across Solid Tumors Following Atezolizumab Treatments: A Tumor Growth Inhibition‐Overall Survival Modeling Framework

2021 · External reference

Explainable Deep Learning for Tumor Dynamic Modeling and Overall Survival Prediction Using Neural‐ODE

10.1038/s41540-023-00317-1 · 2023 · External reference

Tumor Growth and Overall Survival Modeling to Support Decision Making in Phase Ib/II Trials: A Comparison of the Joint and Two‐Stage Approaches

2024 · External reference

A Multistate Model for Early Decision‐Making in Oncology

10.1002/bimj.201800250 · 2020 · External reference

Clinical Pharmacology of Vc‐MMAE Antibody‐Drug Conjugates in cancer Patients: Learning From Eight First‐In‐Human Phase 1 Studies

2020 · External reference

Subcutaneous Administration of Rituximab (MabThera) and Trastuzumab (Herceptin) Using Hyaluronidase

10.1038/bjc.2013.371 · 2013 · External reference

Daratumumab Subcutaneous Formulation for the Treatment of Multiple Myeloma

10.1080/14712598.2020.1806231 · 2020 · External reference

Fixed‐Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection Plus Chemotherapy in HER2‐Positive Early Breast cancer (FeDeriCa): A Randomised, Open‐Label, Multicentre, Non‐Inferiority, Phase 3 Study

10.1016/s1470-2045(20)30536-2 · 2021 · External reference

Efficacy and Safety of Subcutaneous and Intravenous Administration of Atezolizumab in Patients With Non‐Small Cell Lung cancer, Including Early‐Stage, Locally Advanced or Metastatic Disease: Updated Results of the IMscin001 and IMscin002 Randomized Studies

10.1016/j.lungcan.2026.109452 · 2026 · External reference